Design, synthesis and development of novel camptothecin drugs.
For almost 5 decades later since it was first discovered in 1958, efforts continue to be made in the medicinal chemistry of camptothecin (CPT) and its derivatives. Thousands of CPT analogues have been prepared. However, many of the earlier CPT derivatives were either too toxic for clinical use or had very poor pharmacokinetics. Efforts in the last 2 decades were most successful and two derivatives, Irinotecan and topotecan, have been clinically approved by the FDA. This review mainly summarizes the design and synthesis of camptothecin drugs in various stages of preclinical or clinical developments.
Liew
Siong Tern
ST
TLC Biopharmaceuticals, Inc. South San Francisco, CA, USA.
Yang
Li-Xi
LX
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin